Skip to main content
. 2011 Feb 17;96(6):932–936. doi: 10.3324/haematol.2010.033159

Figure 1.

Figure 1.

Alemtuzumab serum concentration-time profile in relation to the mean lymphocyte counts in patients treated with alemtuzumab. [□] Indicates median lymphocyte values (109/μL) reported during the 12 months after start of therapy; [●], alemtuzumab concentration (μg/mL) reported during the first 100 days after start of therapy.